Cerebrolysin Research: What 971 Studies Show (2026) | RetatrutideCompare

Cerebrolysin — 971 studies indexed on PubMed. Multi-modal neurotrophic effects mimicking BDNF/CNTF signaling; protein synthesis modulation; neuroprotection in ischemia models. Half-life: Variable (mixture). FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Cerebrolysin?

There are approximately 971 studies indexed on PubMed that mention Cerebrolysin (Porcine brain peptide complex), based on a search last updated 2026-06-18.

Is Cerebrolysin FDA-approved?

FDA status: Not FDA-approved.

How does Cerebrolysin work?

Multi-modal neurotrophic effects mimicking BDNF/CNTF signaling; protein synthesis modulation; neuroprotection in ischemia models.

Multi-modal neurotrophic effects mimicking BDNF/CNTF signaling; protein synthesis modulation; neuroprotection in ischemia models.

Reference facts

Also known as
Porcine brain peptide complex
Category
Nootropic & Cognitive
Mechanism of action
Multi-modal neurotrophic effects mimicking BDNF/CNTF signaling; protein synthesis modulation; neuroprotection in ischemia models.
Targets
Multi-target neurotrophic signaling
Indications under research or approved
Approved Europe/Asia (ischemic stroke, vascular dementia, TBI); not US-approved
Regulatory status (reference entry)
Not FDA-approved
Half-life
Variable (mixture)
Sequence notes
Mixture of low-molecular-weight peptides and free amino acids (~85% free aa, 15% peptides <10 kDa) derived from enzymatic breakdown of porcine brain protein.
Originator / sponsor
Ever Neuro Pharma (Austria)
First reported
1949

Primary References

Explore research articles about Cerebrolysin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.